382 related articles for article (PubMed ID: 37629010)
1. Glucagon and Its Receptors in the Mammalian Heart.
Neumann J; Hofmann B; Dhein S; Gergs U
Int J Mol Sci; 2023 Aug; 24(16):. PubMed ID: 37629010
[TBL] [Abstract][Full Text] [Related]
2. Role of Dopamine in the Heart in Health and Disease.
Neumann J; Hofmann B; Dhein S; Gergs U
Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902474
[TBL] [Abstract][Full Text] [Related]
3. Function and Role of Histamine H
Neumann J; Hofmann B; Kirchhefer U; Dhein S; Gergs U
Pharmaceuticals (Basel); 2023 May; 16(5):. PubMed ID: 37242517
[TBL] [Abstract][Full Text] [Related]
4. Robust anti-obesity and metabolic effects of a dual GLP-1/glucagon receptor peptide agonist in rodents and non-human primates.
Henderson SJ; Konkar A; Hornigold DC; Trevaskis JL; Jackson R; Fritsch Fredin M; Jansson-Löfmark R; Naylor J; Rossi A; Bednarek MA; Bhagroo N; Salari H; Will S; Oldham S; Hansen G; Feigh M; Klein T; Grimsby J; Maguire S; Jermutus L; Rondinone CM; Coghlan MP
Diabetes Obes Metab; 2016 Dec; 18(12):1176-1190. PubMed ID: 27377054
[TBL] [Abstract][Full Text] [Related]
5. Receptor identification and physiological characterisation of glucagon-like peptide-2 in the rat heart.
Angelone T; Filice E; Quintieri AM; Imbrogno S; Amodio N; Pasqua T; Pellegrino D; Mulè F; Cerra MC
Nutr Metab Cardiovasc Dis; 2012 Jun; 22(6):486-94. PubMed ID: 21186112
[TBL] [Abstract][Full Text] [Related]
6. Evidence for a lack of inotropic and chronotropic effects of glucagon and glucagon receptors in the human heart.
Aranda-Domene R; Orenes-Piñero E; Arribas-Leal JM; Canovas-Lopez S; Hernández-Cascales J
Cardiovasc Diabetol; 2023 May; 22(1):128. PubMed ID: 37254135
[TBL] [Abstract][Full Text] [Related]
7. Glucagon and Glucagon-like Peptide-1 Receptors: Promising Therapeutic Targets for an Effective Management of Diabetes Mellitus.
Abbas G; Haq QMI; Hamaed A; Al-Sibani M; Hussain H
Curr Pharm Des; 2020; 26(4):501-508. PubMed ID: 32003684
[TBL] [Abstract][Full Text] [Related]
8. Effects of the once-weekly glucagon-like peptide-1 receptor agonist dulaglutide on ambulatory blood pressure and heart rate in patients with type 2 diabetes mellitus.
Ferdinand KC; White WB; Calhoun DA; Lonn EM; Sager PT; Brunelle R; Jiang HH; Threlkeld RJ; Robertson KE; Geiger MJ
Hypertension; 2014 Oct; 64(4):731-7. PubMed ID: 24980665
[TBL] [Abstract][Full Text] [Related]
9. Responsiveness to glucagon in fetal hearts. Species variability and apparent disparities between changes in beating, adenylate cyclase activation, and cyclic AMP concentration.
Wildenthal K; Allen DO; Karlsson J; Wakeland JR; Clark CM
J Clin Invest; 1976 Mar; 57(3):551-8. PubMed ID: 175087
[TBL] [Abstract][Full Text] [Related]
10. Variation in the Evolution and Sequences of Proglucagon and the Receptors for Proglucagon-Derived Peptides in Mammals.
Irwin DM
Front Endocrinol (Lausanne); 2021; 12():700066. PubMed ID: 34322093
[TBL] [Abstract][Full Text] [Related]
11. Oxyntomodulin increases intrinsic heart rate in mice independent of the glucagon-like peptide-1 receptor.
Sowden GL; Drucker DJ; Weinshenker D; Swoap SJ
Am J Physiol Regul Integr Comp Physiol; 2007 Feb; 292(2):R962-70. PubMed ID: 17038440
[TBL] [Abstract][Full Text] [Related]
12. Refinement of glucagon-like peptide 1 docking to its intact receptor using mid-region photolabile probes and molecular modeling.
Miller LJ; Chen Q; Lam PC; Pinon DI; Sexton PM; Abagyan R; Dong M
J Biol Chem; 2011 May; 286(18):15895-907. PubMed ID: 21454562
[TBL] [Abstract][Full Text] [Related]
13. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.
Malavazos AE; Iacobellis G; Dozio E; Basilico S; Di Vincenzo A; Dubini C; Menicanti L; Vianello E; Meregalli C; Ruocco C; Ragni M; Secchi F; Spagnolo P; Castelvecchio S; Morricone L; Buscemi S; Giordano A; Goldberger JJ; Carruba M; Cinti S; Corsi Romanelli MM; Nisoli E
Eur J Prev Cardiol; 2023 Jun; 30(8):680-693. PubMed ID: 36799940
[TBL] [Abstract][Full Text] [Related]
14. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene.
Scrocchi LA; Brown TJ; MaClusky N; Brubaker PL; Auerbach AB; Joyner AL; Drucker DJ
Nat Med; 1996 Nov; 2(11):1254-8. PubMed ID: 8898756
[TBL] [Abstract][Full Text] [Related]
15. New developments in the biology of the glucagon-like peptides GLP-1 and GLP-2.
Drucker DJ; Lovshin J; Baggio L; Nian M; Adatia F; Boushey RP; Liu Y; Saleh J; Yusta B; Scrocchi L
Ann N Y Acad Sci; 2000; 921():226-32. PubMed ID: 11193827
[TBL] [Abstract][Full Text] [Related]
16. GIP and GLP-1 as incretin hormones: lessons from single and double incretin receptor knockout mice.
Hansotia T; Drucker DJ
Regul Pept; 2005 Jun; 128(2):125-34. PubMed ID: 15780432
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of the insulinotropic and glucose-lowering actions of zebrafish GIP in mammalian systems: Evidence for involvement of the GLP-1 receptor.
Graham GV; Conlon JM; Abdel-Wahab YH; Gault VA; Flatt PR
Peptides; 2018 Feb; 100():182-189. PubMed ID: 29157578
[TBL] [Abstract][Full Text] [Related]
18. Spatial approximations between residues 6 and 12 in the amino-terminal region of glucagon-like peptide 1 and its receptor: a region critical for biological activity.
Chen Q; Pinon DI; Miller LJ; Dong M
J Biol Chem; 2010 Aug; 285(32):24508-18. PubMed ID: 20529866
[TBL] [Abstract][Full Text] [Related]
19. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?
Grieve DJ; Cassidy RS; Green BD
Br J Pharmacol; 2009 Aug; 157(8):1340-51. PubMed ID: 19681866
[TBL] [Abstract][Full Text] [Related]
20. The autonomic nervous system and cardiac GLP-1 receptors control heart rate in mice.
Baggio LL; Ussher JR; McLean BA; Cao X; Kabir MG; Mulvihill EE; Mighiu AS; Zhang H; Ludwig A; Seeley RJ; Heximer SP; Drucker DJ
Mol Metab; 2017 Nov; 6(11):1339-1349. PubMed ID: 29107282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
